Abstract:Objective: Antipsychotics, such as aripiprazole and risperidone, are often used to treat individuals with schizophrenia. The efficacy as well as safety of aripiprazole in Western populations has been described. The objective of this study is to investigate the efficacy, safety, and tolerability of aripiprazole and risperidone in Chinese Han schizophrenia subjects in mainland China. Method: The 6-week, double-blind, randomized, parallel study was conducted in 5 medical centers in mainland China from November 2007 to March 2011. A total of 279 subjects with a primary DSM-IV diagnosis of schizophrenia were randomly assigned (with a randomization ratio of 1: 1) to aripiprazole (n = 139) or risperidone (n = 140). Efficacy measurements included the Positive and Negative Syndrome Scale (PANSS) total, positive, negative and general psychopathology subscale scores, and Clinical Global Impressions-Severity of Illness (CGI-S), and Improvement scale scores. Extrapyramidal symptoms (EPS), weight gain, serum prolactin level, QTc interval, and self-reported adverse events were also assessed as measures of safety and tolerability. Results: Both the aripiprazole and risperidone groups showed statistically significant improvement of PANSS total, positive, negative, general psychopathology subscale scores, and CGI-S scores from baseline to the endpoint (all p < 0.01). Significant improvement was noted in the first week for both treatment groups. There were no significant differences in efficacy measurements between the two treatment groups. Mean change of PANSS total scores from baseline to the endpoint was -26.8 +/- 18.1 for aripiprazole and -30.0 +/- 17.7 for risperidone, (p = 0.1475). The responder rate was 71% (n = 99) and 76% (n = 107) for aripiprazole and risperidone, respectively, (p = 0.323). The incidences of EPS were similar in the aripiprazole (25%, n = 35) and risperidone groups (24%, n = 34), respectively (p = 0.757). No clinically meaningful effects on QTc interval, QRS duration, or PR interval were observed in either treatment groups. However, the incidence of clinically significant weight gain (p = 0.0118) and hyperprolactinemia (p < 0.001) in the aripiprazole group was significantly lower than in the risperidone group. Conclusion: The study demonstrated that aripiprazole, as well as risperidone, had rapid and persistent efficacy for psychotic symptoms from the first week of therapy. There may be poor efficacy for aripiprazole compared with risperidone for overall improvement, but there were no significant differences in this study. Aripiprazole showed good tolerability with less weight gain and hyperprolactinemia compared with risperidone. The overall efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects were similar to that reported in Western populations. (C) 2014 Published by Elsevier B.V.

Risperidone Versus Haloperidol in Treatment of Acute Manic Episodes of Bipolar Ⅰ Disorder: a Randomized Double-Blind Controlled Muiticenter Study

A double blinded multicenter clinical trial for evaluating the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia

Olanzapine Versus Lithium in the Acute Treatment of Bipolar Mania: A Double-Blind, Randomized, Controlled Trial

Efficacy and Safety of Long-Acting Risperidone on Early Onset Schizophrenia in Adolescent Patients

Risperidone Versus Haloperidol in the Treatment of Acute Exacerbations of Chronic Inpatients with Schizophrenia: a Randomized Double-Blind Study

Haloperidol alone or in combination for acute mania

A Multicenter Study of Risperidone Treatment for Acute Agitation in Patients with Schizophrenia

Double-blind Comparison of Ziprasidone and Risperidone in the Treatment of Chinese Patients with Acute Exacerbation of Schizophrenia

Efficacy and Safety of Aripiprazole in the Treatment of Schizophrenia: a Randomized, Double-Blind, Risperidone Controlled, Multicenter Study

Double-blind,double-dummy and randomized controlled study of aripiprazole in the treatment of acute schizophrenia

Aripiprazole and risperidone in treatment of the patients with schizophrenia: a randomly clinical trial

Aripiprazole Versus Lithium in Management of Acute Mania: a Randomized Clinical Trial

Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.

Prolactin Levels in Male Schizophrenic Patients Treated with Risperidone and Haloperidol: a Double-Blind and Randomized Study

Efficacy and Safety of Quetiapine in the Treatment of Bipolar Acute Mania: a Randomized, Double-Blind, Lithium-Controlled Multicenter Study

Comparison of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorder and attention deficit-hyperactivity disorder: A randomized clinical trial

A systematic review and network meta-analysis on comparative efficacy, acceptability, and safety of treatments in acute bipolar mania in youths

Safety evaluation of iloperidone and risperidone in the treatment of schizophrenia

Study on Efficacy and Safety of Risperidone in Treatment of Different Kinds of Schizophrenia

Comparison the clinical effects and safety of amisulpride and risperidone in the treatment of schizophrenia

Randomized,double-blind,controlled,multicenter Clinical Trial of Sustained-Release Divalproex Versus Lithium Carbonate in the Treatment of Manic Episodes of Bipolar Disorder Type Ⅰ